Triple-Phase CT: Indications and Protocol
Direct Answer
Triple-phase CT of the liver is indicated for characterization and detection of hepatocellular carcinoma (HCC) in patients with chronic liver disease or cirrhosis, utilizing arterial, portal venous, and delayed phases to capture the hallmark imaging features of arterial hyperenhancement and delayed washout. 1
Primary Indication
Triple-phase (multiphase) CT is specifically designed for evaluating liver lesions in at-risk patients, particularly those with:
- Chronic liver disease or cirrhosis
- Known or suspected HCC
- Indeterminate liver lesions requiring characterization (LI-RADS 3 or 4 observations)
- Preoperative staging of confirmed HCC
The protocol exploits the characteristic enhancement pattern of HCC—arterial hyperenhancement with delayed washout—which has 89% sensitivity and 96% specificity for HCC diagnosis. 1
Recommended Protocol
Contrast Administration
- Injection rate: 4 ml/sec is superior to 2 ml/sec 2
- Achieves earlier peak aortic enhancement (24 seconds vs 36 seconds)
- Higher peak aortic attenuation (330 HU vs 186 HU)
- Similar hepatic enhancement but better tumor conspicuity
- Contrast volume: 60% nonionic contrast material 2
Phase Timing
The three phases must be precisely timed:
Late Arterial Phase (most critical)
- Delay: 25 seconds after injection start with 4 ml/sec rate 2
- This phase provides the highest sensitivity for small HCC detection
- Captures arterial hyperenhancement of HCC nodules
Portal Venous Phase
- Delay: Approximately 60-70 seconds 2
- Provides anatomic detail and vascular mapping
- Less sensitive for small HCC detection but necessary for complete evaluation
Delayed/Equilibrium Phase
- Delay: 3-5 minutes post-injection
- Captures washout appearance characteristic of HCC
- Second-highest liver-tumor contrast after arterial phase 2
Critical Protocol Considerations
Why Three Phases Matter
Research demonstrates that late arterial phase imaging is essential—it detects 35 of 109 HCCs that were only visible or most conspicuous in this phase. 2 The portal venous phase alone has significantly lower liver-tumor contrast and limited value for detecting small HCCs. 2
Early vs. Late Arterial Phase
Do not acquire two arterial phases—studies show no improvement in sensitivity or positive predictive value when adding an early arterial phase to late arterial phase imaging (87.1% sensitivity for both). 3 This avoids unnecessary radiation exposure without diagnostic benefit.
When to Add Noncontrast Phase
The standard triple-phase protocol does not require a noncontrast phase for initial HCC characterization. 4 However, add a noncontrast series when:
- Evaluating patients after liver-directed therapy 1
- Assessing for hemorrhage or calcification
Performance Characteristics
For lesions <2 cm in cirrhotic patients:
- Dual-phase CT sensitivity: 53% 4
- Triple-phase CT sensitivity: 61-73% 4
- Triple-phase CT accuracy: 49-68% for lesion characterization 4
The delayed phase washout is critical for HCC diagnosis and significantly improves detection compared to arterial phase alone. 4
Common Pitfalls to Avoid
Single-phase imaging is inadequate—it does not allow proper lesion characterization and misses the diagnostic hallmark of HCC. 1
Wrong timing destroys diagnostic value—a 20-second delay with 4 ml/sec injection yields significantly lower tumor enhancement than 25-second delay. 2
Skipping the delayed phase—this phase provides the second-highest liver-tumor contrast and is essential for demonstrating washout. 2
Using 2 ml/sec injection rate—this slower rate provides inferior tumor conspicuity despite similar hepatic enhancement. 2
Alternative Considerations
While triple-phase CT is the standard, multiphase MRI with extracellular or hepatobiliary agents performs similarly and may be preferred in certain patients. 1 MRI with gadoxetate shows higher sensitivity (76-97%) for small HCC <2 cm compared to CT (53%). 4
For staging confirmed HCC, if diagnostic multiphase imaging has already been performed, repeat triple-phase CT is unnecessary—proceed directly to chest CT for metastatic evaluation as required by transplant protocols. 1